Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

19.02 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	307
Open	19.02
Bid (Size)	19.08 (100)
Ask (Size)	20.49 (100)
Prev. Close	19.02
Today's Range	19.02 - 19.02
52wk Range	3.420 - 30.00
Shares Outstanding	36,130,121
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

UroGen (URGN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

UroGen (URGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress ↗

March 02, 2026

Via Chartmill

Performance

YTD	-16.2%	-16.2%
1 Month	-3.5%	-3.5%
3 Month	-33.2%	-33.2%
6 Month	-2.6%	-2.6%
1 Year	+105.2%	+105.2%

More News

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

March 02, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

March 02, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

February 27, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

February 23, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

February 04, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

January 05, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗

December 26, 2025

Via The Motley Fool

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen (URGN) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Via The Motley Fool

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗

November 06, 2025

Via Chartmill

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

November 06, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

November 06, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

November 04, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

October 30, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

October 27, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 24, 2025

Via Benzinga

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

October 02, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at Upcoming Investor Conferences

August 21, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen (URGN) Q2 Revenue Rises 11% ↗

August 07, 2025

Via The Motley Fool

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?

Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.

What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?

UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?

The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market

What is the current price of UroGen Pharma Ltd. - Ordinary Shares?

The current price of UroGen Pharma Ltd. - Ordinary Shares is 19.02

When was UroGen Pharma Ltd. - Ordinary Shares last traded?

The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 03/02/26 04:00 PM ET

What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?

The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 687.19M

How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?

UroGen Pharma Ltd. - Ordinary Shares has 687M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.